特异性促炎症消退介质在银屑病中的研究进展

doi:10.35541/cjd.20240503

Abstract

Abstract: 【Abstract】 Psoriasis is a chronic inflammatory skin disorder characterized by aberrant activation of T lymphocytes and excessive proliferation of keratinocytes, with persistent inflammation being the central pathological feature. Specialized pro-resolving mediators （SPMs） exert anti-inflammatory effects through various mechanisms, actively facilitating the resolution of inflammation. The dual regulatory role in inflammation has garnered attention in the study of psoriasis pathogenesis. This review aims to consolidate recent advancements in SPMs, explore their specific roles in psoriasis pathogenesis, and evaluate their potential clinical application.

Key words: Psoriasis, Fatty acids, unsaturated, Lipoxins, Specialized pro-resolving mediators, Therapy, Inflammation mediators

Huang Shudai, Zhou Xuyue, Zhang Jiaan, Chen Kun. Role of specialized pro-resolving mediators in psoriasis[J]. Chinese Journal of Dermatology,2025,e0240503. doi:10.35541/cjd.20240503

References ［37］

［1］	Fredman G, Serhan CN. Specialized pro⁃resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease［J］. Nat Rev Cardiol, 2024,21（11）:808⁃823. doi: 10.1038/s41569⁃023⁃00984⁃x.
［2］	Wang X, Ma R, Shi R, et al. Sex differences in the association between plasma polyunsaturated fatty acids levels and moderate⁃to⁃severe plaque psoriasis severity: a cross⁃sectional and longitudinal study［J］. J Transl Med, 2023,21（1）:834. doi: 10. 1186/s12967⁃023⁃04726⁃y.
［3］	Merlin J, Park J, Vandekolk TH, et al. Multipathway in vitro pharmacological characterization of specialized proresolving G protein⁃coupled receptors［J］. Mol Pharmacol, 2022,101（4）:246⁃256. doi: 10.1124/molpharm.121.000422.
［4］	Hu F, Qu Z, Chen K, et al. Lipoxin A4 ameliorates imiquimod⁃induced psoriasis⁃like dermatitis via promoting the regression of inflammation［J］. Clin Cosmet Investig Dermatol, 2023,16:2103⁃2111. doi: 10.2147/CCID.S418467.
［5］	Schottelius AJ, Giesen C, Asadullah K, et al. An aspirin⁃triggered lipoxin A4 stable analog displays a unique topical anti⁃inflammatory profile［J］. J Immunol, 2002,169（12）:7063⁃7070. doi: 10.4049/jimmunol.169.12.7063.
［6］	Brown AL. And the germline beat （AML） goes on［J］. Blood, 2022,139（8）:1126⁃1128. doi: 10.1182/blood.2021013771.
［7］	Gao J, Su Y, Wang Z. Lung inflammation resolution by RvD1 and RvD2 in a receptor⁃dependent manner［J］. Pharmaceutics, 2023,15（5）:1527. doi: 10.3390/pharmaceutics15051527.
［8］	Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution［J］. FASEB J, 2007,21（12）:3162⁃3170. doi: 10.1096/fj.07⁃8473com.
［9］	Liang Z, Yue H, Xu C, et al. Protectin DX relieve hyperoxia⁃induced lung injury by protecting pulmonary endothelial glycocalyx［J］. J Inflamm Res, 2023,16:421⁃431. doi: 10.2147/JIR.S391765.
［10］	Chen O, Donnelly CR, Ji RR. Regulation of pain by neuro⁃immune interactions between macrophages and nociceptor sensory neurons［J］. Curr Opin Neurobiol, 2020,62:17⁃25. doi: 10.1016/j.conb.2019.11.006.
［11］	Belayev L, Hong SH, Menghani H, et al. Docosanoids promote neurogenesis and angiogenesis, blood⁃brain barrier integrity, penumbra protection, and neurobehavioral recovery after experimental ischemic stroke［J］. Mol Neurobiol, 2018,55（8）:7090⁃7106. doi: 10.1007/s12035⁃018⁃1136⁃3.
［12］	Leroy V, Cai J, Filiberto A, et al. Resolution of post⁃lung transplant ischemia⁃reperfusion injury is mediated via resolvin D1⁃Alx/FPR2 and maresin 1⁃LGR6 receptor signaling［J］. The Journal of Heart and Lung Transplantation, 2021,40（4）:s55⁃s56. doi:10.1016/j.healun.2021.01.1876.
［13］	Chiang N, Libreros S, Norris PC, et al. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions［J］. J Clin Invest, 2023,133（2）:e168084. doi: 10.1172/JCI168084.
［14］	Sun S, Wang L, Wang J, et al. Maresin1 prevents sepsis⁃induced acute liver injury by suppressing NF⁃κB/Stat3/MAPK pathways, mitigating inflammation［J］. Heliyon, 2023,9（11）:e21883. doi: 10.1016/j.heliyon.2023.e21883.
［15］	Saito⁃Sasaki N, Sawada Y, Mashima E, et al. Maresin⁃1 suppresses imiquimod⁃induced skin inflammation by regulating IL⁃23 receptor expression［J］. Sci Rep, 2018,8（1）:5522. doi: 10.1038/s41598⁃018⁃23623⁃9.
［16］	Xu J, Duan X, Hu F, et al. Resolvin D1 attenuates imiquimod⁃induced mice psoriasiform dermatitis through MAPKs and NF⁃κB pathways［J］. J Dermatol Sci, 2018,89（2）:127⁃135. doi: 10. 1016/j.jdermsci.2017.10.016.
［17］	Sawada Y, Honda T, Nakamizo S, et al. Resolvin E1 attenuates murine psoriatic dermatitis［J］. Sci Rep, 2018,8（1）:11873. doi: 10.1038/s41598⁃018⁃30373⁃1.
［18］	Park KD, Kim N, Kang J, et al. Protectin D1 reduces imiquimod⁃induced psoriasiform skin inflammation［J］. Int Immunopharmacol, 2021,98:107883. doi: 10.1016/j.intimp.2021.107883.
［19］	Yuan J, Lin F, Chen L, et al. Lipoxin A4 regulates M1/M2 macrophage polarization via FPR2⁃IRF pathway［J］. Inflammopharmacology, 2022,30（2）:487⁃498. doi: 10.1007/s10787⁃022⁃00942⁃y.
［20］	Maderna P, Cottell DC, Toivonen T, et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin⁃derived peptide⁃stimulated phagocytosis［J］. FASEB J, 2010,24（11）:4240⁃4249. doi: 10.1096/fj.10⁃159913.
［21］	Hu F, Liu XX, Wang X, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF⁃κB pathways［J］. J Dermatol Sci, 2015,78（3）:181⁃188. doi: 10.1016/j.jdermsci.2015.03.009.
［22］	Kelly AG, Panigrahy D. Targeting angiogenesis via resolution of inflammation［J］. Cold Spring Harb Perspect Med, 2023,13（3）:a041172. doi: 10.1101/cshperspect.a041172.
［23］	Laban A, Atallah R, Eldahshan R, et al. Assessment of retinal vasculature in patients with psoriasis［J］. International Journal of Medical Arts, 2022,4（11）:2767⁃2774. doi:10.21608/ijma.2023. 176787.1560.
［24］	Sun W, Ma J, Zhao H, et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA⁃146a⁃5p in rheumatoid arthritis［J］. Arthritis Res Ther, 2020,22（1）:61. doi: 10.1186/s13075⁃020⁃2133⁃2.
［25］	Rajasagi NK, Reddy PB, Suryawanshi A, et al. Controlling herpes simplex virus⁃induced ocular inflammatory lesions with the lipid⁃derived mediator resolvin E1［J］. J Immunol, 2011,186（3）:1735⁃1746. doi: 10.4049/jimmunol.1003456.
［26］	Sorokin AV, Arnardottir H, Svirydava M, et al. Comparison of the dietary omega⁃3 fatty acids impact on murine psoriasis⁃like skin inflammation and associated lipid dysfunction［J］. J Nutr Biochem, 2023,117:109348. doi: 10.1016/j.jnutbio.2023.109348.
［27］	Morin S, Simard M, Rioux G, et al. Alpha⁃linolenic acid modulates T cell incorporation in a 3D tissue⁃engineered psoriatic skin model［J］. Cells, 2022,11（9）:1513. doi: 10.3390/cells11091513.
［28］	Morin S, Tremblay A, Dumais E, et al. Eicosapentaenoic acid influences the lipid profile of an in vitro psoriatic skin model produced with T cells［J］. Biomolecules, 2023,13（9）:1413. doi: 10.3390/biom13091413.
［29］	Escobar SO, Achenbach R, Iannantuono R, et al. Topical fish oil in psoriasis⁃⁃a controlled and blind study［J］. Clin Exp Dermatol, 1992,17（3）:159⁃162. doi: 10.1111/j.1365⁃2230.1992.tb00194.x.
［30］	Li N, Qin Y, Dai D, et al. Transdermal delivery of therapeutic compounds with nanotechnological approaches in psoriasis［J］. Front Bioeng Biotechnol, 2021,9:804415. doi: 10.3389/fbioe. 2021.804415.
［31］	Furutani K, Chen O, McGinnis A, et al. Novel proresolving lipid mediator mimetic 3⁃oxa⁃PD1n⁃3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin⁃2 in mice［J］. Pain, 2023,164（6）:1340⁃1354. doi: 10.1097/j.pain.000 0000000002824.
［32］	Song CH, Wang R, Zhao ZK, et al. Leptin modulates the differentiation of keratinocytes via autophagy in psoriasis patients with metabolic syndrome. Int J Dermatol Venerol, 2024, 7（3）:121⁃130. doi: 10.1097/JD9.0000000000000353.
［33］	Martínez⁃Fernández L, Burgos M, Sáinz N, et al. Maresin 1 exerts a tissue⁃specific regulation of adipo⁃hepato⁃myokines in diet⁃induced obese mice and modulates adipokine expression in cultured human adipocytes in basal and inflammatory conditions［J］. Biomolecules, 2023,13（6）:919. doi: 10.3390/biom13060919.
［34］	Salazar J, Pirela D, Nava M, et al. Specialized proresolving lipid mediators: a potential therapeutic target for atherosclerosis［J］. Int J Mol Sci, 2022,23（6）:3133. doi: 10.3390/ijms23063133.
［35］	Yang WS, Wang JL, Wu W, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease［J］. Acta Pharmacol Sin, 2023,44（1）:19⁃31. doi: 10.1038/s41401⁃022⁃00944⁃0.
［36］	Byrne L, Guiry PJ. Advances in the chemistry and biology of specialised pro⁃resolving mediators （SPMs）［J］. Molecules, 2024,29（10）:2233. doi: 10.3390/molecules29102233.
［37］	Rahman M, Akhter S, Ahmad J, et al. Nanomedicine⁃based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy［J］. Expert Opin Drug Deliv, 2015,12（4）:635⁃652. doi: 10.1517/17425247.2015.982088.

[1]	Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737.
[2]	Shi Rongcan¹, ², Yu Zengyang², ³, Luo Qingqiong², Ma Rui¹, ², Jiang Xingyu¹, ², Wang Yuanyuan¹, ², Cai Jiangluyi¹, ², Shi Yuling¹, ². Palmitoyl-proteomic profiles of psoriatic lesions and their role in inflammatory responses: a preliminary study [J]. Chinese Journal of Dermatology, 2026, 59(8): 738-749.
[3]	Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.
[4]	Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787.
[5]	Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.
[6]	Wang Linlin, Cao Lijuan, Chen Liuqing, Li Dongsheng, Hu Yanyan. Efficacy and safety of hemoporfin-mediated photodynamic therapy for port-wine stains on the extremities: a retrospective analysis [J]. Chinese Journal of Dermatology, 2026, 59(7): 637-644.
[7]	Yuwen Tianyi¹, Zhou Zizhen¹, Tian Jingyu¹, Chen Sihan², Li Min², Zhang Fengyuan¹, Gu Heng, ², Chen Xu, ². Expression of the glutaminase 1/ammonia metabolism axis in keratinocytes in ultraviolet B-induced acute skin injury and psoriatic skin inflammation [J]. Chinese Journal of Dermatology, 2026, 59(7): 654-661.
[8]	Zhang Guolong, Zhao Zijun. Aminolevulinic acid-based photodynamic therapy for cutaneous squamous cell carcinoma: current status, challenges, and perspectives [J]. Chinese Journal of Dermatology, 2026, 59(7): 626-631.
[9]	Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636.
[10]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline for the clinical application of narrowband ultraviolet B phototherapy in dermatology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 595-610.
[11]	Photodynamic Therapy Research Cooperative Group, Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology & Photodynamic Therapy, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Guideline for the clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of condyloma acuminatum （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 611-618.
[12]	Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.
[13]	Sun Songpeng, Long Junhong, Cao Bo, Xu Yue, Zhang Xiang′an, Cao Hui, Xie Jun, Gui Ping, Sun Xiaojun, Zhang Bo, Xu Zhijie, Li Jin′an, Wang Zhigang, Wu Wei, Yang Huiju, Wei Ping, Liu Congcong, Shen Qingbo, Yu Fan, Chu Hongchuan, Zhou Yangyang, Liu Jiaxin, Liu Yan, Huo Xingxiao, Chen Hang, Jing Tao, Gao Jing, Wang Yanxun, Wang Rui, Li Zhenyu, Zhang Shuxin. Efficacy and safety of Fuzhiqing ointment versus triamcinolone acetonide and econazole nitrate cream in the treatment of chronic perianal eczema: a multicenter, randomized, double-blind, controlled, equivalence trial [J]. Chinese Journal of Dermatology, 2026, 59(6): 564-570.
[14]	Xu Zhuohong, Zhou Huan, Hu Yu, Gu Heng. Balneotherapy in skin diseases [J]. Chinese Journal of Dermatology, 2026, 59(5): 482-485.
[15]	Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 407-418.

Role of specialized pro-resolving mediators in psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［37］

Related Articles 15

Metrics

Comments

Recommended 10